Treatment for obesity
The present invention relates to a method for treating or preventing obesity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds. The invention further relates to methods for reducing body weight and/or reducing food intake in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds.
1. A method for treating pathological eating in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I):
or a pharmaceutically acceptable salt or ester thereof;
wherein R is a member selected from the group consisting of alkyl of 1 to 8 carbon atoms, halogen, alkoxy of 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy of 1 to 3 carbon atoms;
x is 0;
R 1 and R 2 are hydrogen;
thereby treating the pathological eating.
2. A method for reducing or preventing body weight gain in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I):
or a pharmaceutically acceptable salt or ester thereof;
wherein R is a member selected from the group consisting of alkyl of 1 to 8 carbon atoms, halogen, alkoxy of 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy of 1 to 3 carbon atoms;
x is 0;
R 1 and R2 are hydrogen;
wherein the subject reduces body weight or prevents body weight gain.
3. A method for decreasing food consumption in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I):
or a pharmaceutically acceptable salt or ester thereof;
wherein R is a member selected from the group consisting of alkyl of 1 to 8 carbon atoms, halogen, alkoxy of 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy of 1 to 3 carbon atoms;
x is 0;
R 1 and R 2 are hydrogen;
wherein the subject reduces food intake.
4. The method of claim 1 , wherein the compound of Formula I is an enantiomer of Formula I substantially free of other enantiomers or an enantiomeric mixture wherein one enantiomer of Formula I predominates.
5. The method of claim 4 , wherein the enantiomer of Formula I substantially free of other enantiomers is the compound of Formula Ib or an enantiomeric mixture wherein the compound of Formula Ib predominates:
or a pharmaceutically acceptable salt or ester thereof.
6. The method of claim 5 , wherein the compound of Formula Ib predominates to the extent of about 98% or greater.
7. The method of claim 1 , wherein the compound of Formula I is administered orally.
8. The method of claim 1 , wherein the compound of Formula I is administered in the form of a capsule or tablet at a dose of about 10 mg to about 1000 mg without any excipients.
9. The method of claim 2 , wherein the compound of Formula I is an enantiomer of Formula I substantially free of other enantiomers or an enantiomeric mixture wherein one enantiomer of Formula I predominates.
10. The method of claim 9 , wherein the enantiomer of Formula I substantially free of other enantiomers is the compound of Formula Ib or an enantiomeric mixture wherein the compound of Formula Ib predominates:
or a pharmaceutically acceptable salt or ester thereof.
11. The method of claim 10 , wherein the compound of Formula Ib predominates to the extent of about 98% or greater.
12. The method of claim 2 , wherein the compound of Formula I is administered orally.
13. The method of claim 2 , wherein the compound of Formula I is administered in the form of a capsule or tablet at a dose of about 10 mg to about 1000 mg without any excipients.
14. The method of claim 3 , wherein the compound of Formula I is an enantiomer of Formula I substantially free of other enantiomers or an enantiomeric mixture wherein one enantiomer of Formula I predominates.
15. The method of claim 14 , wherein the enantiomer of Formula I substantially free of other enantiomers is the compound of Formula Ib or an enantiomeric mixture wherein the compound of Formula Ib predominates:
or a pharmaceutically acceptable salt or ester thereof.
16. The method of claim 15 , wherein the compound of Formula Ib predominates to the extent of about 98% or greater.
17. The method of claim 3 , wherein the compound of Formula I is administered orally.
18. The method of claim 3 , wherein the compound of Formula I is administered in the form of a capsule or tablet at a dose of about 10 mg to about 1000 mg without any excipients.
19. A method for treating obesity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I):
or a pharmaceutically acceptable salt or ester thereof;
wherein R is a member selected from the group consisting of alkyl of 1 to 8 carbon atoms, halogen, alkoxy of 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy of 1 to 3 carbon atoms;
x is 0; and
R 1 and R 2 are hydrogen;
thereby treating the obesity.
20. The method of claim 19 , wherein the compound of Formula I is an enantiomer of Formula I substantially free of other enantiomers or an enantiomeric mixture wherein one enantiomer of Formula I predominates.
21. The method of claim 20 , wherein the enantiomer of Formula I substantially free of other enantiomers is the compound of Formula Ib or an enantiomeric mixture wherein the compound of Formula Ib predominates:
or a pharmaceutically acceptable salt or ester thereof.
22. The method of claim 21 , wherein the compound of Formula Ib predominates to the extent of about 98% or greater.
23. The method of claim 19 , wherein the compound of Formula I is administered orally.
24. The method of claim 19 , wherein the compound of Formula I is administered in the form of a capsule at a dose of about 10 mg to about 1000 mg without any excipients.